MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces its half-year results for the period ended June 30, 2025, as approved by the Board of Directors on October 16, 2025, and provides an update on its clinical, industrial and financial developments. Bruno Lafont, Chief Executive Officer and co-founder of NFL Bioscienc